Abstract: The present disclosure generally relates to auditory nerve stimulation to create the perception of sound in the brain of a subject such as an animal or human being. In one form, a system includes an implantable electrode array including a plurality of spaced apart micro-needles. The system also includes a first electrical lead electrically coupled to and extending from the implantable electrode array, and an auditory signal device configured to produce one or more electrical signals representative of communications received from an external processor. An interposer is configured to electrically couple the implantable electrode array and the auditory signal device in an arrangement where one or more electrical signals produced by the auditory signal device may be transmitted through the first electrical lead to the implantable electrode array. Various novel stimulation strategies can be employed, such as place modulated stimulation signals.

Abstract: An ediscovery system filters a document corpus to identify a filtered document set. The filtered document set is further analyzed to identify a production document set. Documents of the document corpus are stored in one of online storage and nearline storage, nearline storage providing slower access times. Documents added to the production set and/or filtered document set are moved to online storage if not already present. A countdown is associated with each document in the online storage and the document is moved to nearline storage on expiration of the counter. For each document moved, a placeholder file is retained in online storage that includes searchable text of the document. Documents in the production set may have a countdown that is longer for documents in the filtered document set. Documents in the filtered document set may have a countdown that is longer than remaining documents in the document corpus.

Abstract: An ediscovery system filters a document corpus to identify a filtered document set. The filtered document set is further analyzed to identify a production document set. Documents of the document corpus are stored in one of online storage and nearline storage, nearline storage providing slower access times. Documents added to the production set and/or filtered document set are moved to online storage if not already present. A countdown is associated with each document in the online storage and the document is moved to nearline storage on expiration of the counter. For each document moved, a placeholder file is retained in online storage that includes searchable text of the document. Documents in the production set may have a countdown that is longer for documents in the filtered document set. Documents in the filtered document set may have a countdown that is longer than remaining documents in the document corpus.

Abstract: A pharmaceutical composition comprises nanoparticles comprising a poorly water soluble drug, a poorly aqueous soluble non-ionizable polymer, and an amine-functionalized methacrylate copolymer.

Abstract: A pharmaceutical composition comprises nanoparticles comprising a poorly water-soluble drug, a poorly aqueous soluble non-ionizable cellulosic polymer, and a poorly aqueous soluble polymeric amphiphilic non-ionizable block copolymer.

Abstract: A pharmaceutical composition comprises nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a poorly aqueous soluble non-ionizable polymer.

Abstract: A pharmaceutical composition comprises nanoparticles comprising a poorly water-soluble drug, a poorly aqueous soluble non-ionizable cellulosic polymer, and a poorly aqueous soluble polymeric amphiphilic non-ionizable block copolymer.

Abstract: A pharmaceutical composition comprises nanoparticles comprising a poorly water soluble drug, a poorly aqueous soluble non-ionizable polymer, and an amine-functionalized methacrylate copolymer.

Abstract: A pharmaceutical composition comprises nanoparticles comprising a poorly water soluble drug, a poorly aqueous soluble non-ionizable polymer, and an anionic cellulosic polymer.

Abstract: A pharmaceutical composition comprises nanoparticles comprising ionizable, poorly water soluble cellulosic polymers.

Abstract: A pharmaceutical composition comprises nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a poorly aqueous soluble non-ionizable polymer.

Abstract: A pharmaceutical composition comprises nanoparticles comprising a poorly water-soluble drug and an enteric polymer, and casein.

Abstract: A highly porous, fast-disintegrating binder suitable for pharmaceutical applications and methods of making the same are disclosed, the binder comprising microporous particles of an aqueous-soluble cellulosic polymer and a wicking agent. Pharmaceutical compositions and fast-disintegrating dosage forms containing the binder are also disclosed.

Abstract: The present invention is related to an oral dosage form comprising an effective amount of an alkalizing agent and an azithromycin multiparticulate wherein said multiparticulate comprises azithromycin, a glyceride which comprises glyceryl monobehenate, glyceryl dibehenate, glyceryl tribehenate, or a mixture thereof and a poloxamer. Typically, the oral dosage form includes any suitable oral dosing means such as a powder for oral suspension, a unit dose packet or sachet, a tablet or a capsule.

Abstract: The present invention is a method for sex determination in ratites, such as ostriches. The method includes the steps of administering a material that causes sex to be determined to a fertilized ratite egg and incubating the egg until it hatches. Preferably, the administering step includes the step of injecting the material into the egg and preferably before the injecting step, there is the step of drilling a hole into the eggshell of the egg. The material that determines sex in ratites includes natural estrogens or a functionally equivalent amount of its synthetic mimics to cause female development and natural nonaromatizable androgens or a functionally equivalent amount of its synthetic mimics to cause male development. Preferably, the material is estradiol-17beta (for female development) or dihydrotestosterone (for male development). A solution may, for example, be comprised of 1.2 milligrams of estradiol-17beta preferably dissolved in 40 microliters of 95% ethanol, or 7.

Abstract: A method for sex reversal in reptiles and their derivatives comprising the steps of sterilizing the surface of a fertilized egg; injecting the egg with a material that causes sex reversal at least before the first two-thirds of incubation of the egg has passed; and sealing any holes in the egg. In a preferred embodiment, the material that causes sex reversal includes natural estrogens or its synthetic mimics. In an alternative embodiment, the material is applied to the surface of the egg. By practicing the aforesaid method, sex reversal in reptiles and their derivatives is accomplished and viable all female sexed hatchlings are capable of being produced thereby.